Bio-Techne CEO Kim Kelderman Receives RSU Awards

What Happened
Kim Kelderman, Chief Executive Officer of Bio-Techne (TECH), was granted two restricted stock unit (RSU) awards on 2026-08-17 totaling 151,172 RSUs: 57,590 RSUs and 93,582 RSUs. The Form 4 records these derivative awards at $0 (standard reporting for RSUs); no cash was paid. These are equity compensation grants, not open-market purchases or sales.

Key Details

• Transaction date: 2026-08-17; Form 4 filed 2026-08-19 (appears timely within the usual 2-business-day reporting window).
• Awards: 57,590 RSUs (vesting schedule per footnote) and 93,582 RSUs (vesting schedule per footnote).
• Vesting (from filing footnotes):
  • 57,590 RSUs vest as 19,197 on 8/17/2027, 19,197 on 8/17/2028, and 19,196 on 8/17/2029.
  • 93,582 RSUs vest on 8/17/2029.
• RSU meaning: Each RSU represents a contingent right to receive one share of Bio-Techne common stock upon vesting (footnote).
• Price/value: Reported acquisition price $0 on the Form 4 (typical for RSU grants); the filing does not state a cash value in this excerpt.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No indication in this filing of a 10b5-1 plan, sale, exercise, gift, or tax-withholding sale related to these awards.

Context
RSUs are common executive compensation that convert to shares only if and when they vest; they are not immediate purchases or sales and therefore do not directly signal buying or selling intent. The larger award vests in 2029 and the smaller award vests in equal installments across 2027–2029 per the filing.